Absorption, metabolism and excretion of [14C]gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

Xenobiotica

Volumn 44, Issue 6, 2014, Pages 522-530

  Kim, Namtae ^a   Patrick, Lorna ^b   Mair, Stuart ^b   Stevens, Lloyd ^b   Ford, Gill ^c   Birks, Vicky ^c   Lee, Sung Hack ^a  

^a LG Chemical Ltd   (South Korea)

^b Quotient Clinical   (United Kingdom)

^c Quotient Bioresearch Ltd   (United Kingdom)

Author keywords

DPP 4 inhibitor; Human mass balance; Pharmacokinetics

Indexed keywords

CARBON 14; CYTOCHROME P450 3A4; DIMETHYLANILINE MONOOXYGENASE; DRUG METABOLITE; GEMIGLIPTIN; GEMIGLIPTIN C 14; LC 15 0516; LC 15 0635; LC 15 0636; M 285; M 503 2; M 519 2; UNCLASSIFIED DRUG; CARBON; DIPEPTIDYL PEPTIDASE IV INHIBITOR; LC15-0444; PIPERIDONE DERIVATIVE; PROTEIN BINDING; PYRIMIDINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; DRUG ABSORPTION; DRUG EXCRETION; DRUG EXPOSURE; DRUG FECES LEVEL; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG URINE LEVEL; GASTROINTESTINAL TRACT; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA PROTEIN BINDING; RADIOACTIVITY; TIME TO MAXIMUM PLASMA CONCENTRATION; BLOOD; CHEMISTRY; CLINICAL TRIAL; FECES; GASTROINTESTINAL ABSORPTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; CARBON RADIOISOTOPES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FECES; GASTROINTESTINAL ABSORPTION; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; MIDDLE AGED; PIPERIDONES; PROTEIN BINDING; PYRIMIDINES;

EID: 84900451043     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.865856     Document Type: Article

References (14)

1. Blech S, Ludwig-Schwellinger E, Grafe-Mody EU, et al. (2010). The met abolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metab Dispos 38:667-78.
2. Drucker DJ, Nauck MA. (2006). The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-705.
3. European Medicines Agency. (EMA, 2012). Guideline on the investigation of drug interactions. Available from: http://www.ema.europa. e u/docs/en-GB/document-library/Scientific-guideline/2012/07/WC5 00129606.pdf [last accessed 18 June 2013.
4. He H, Tran P, Yin H, et al. (2009). Absorption, metabolism, and excretion of [14Cvildagliptin, a novel dipeptidy l peptidase 4 inhibitor, in humans. Drug Metab Dispos 37:536-44
5. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. (ICH 2009). Guidance on nonclinical sa fety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. Available from http://www.ich.org/ fileadmin/Public-Web-Site/CH-Products/Guidelines/Multidisciplinary/M3-R2/Step4/ M3-R2- Guideline.pdf [last acces sed 18 June 2013.
6. Lim KS, Kim JR, Choi YJ, et al. (2008). Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a doseblock-randomized, double-bli nd, placebo-controlled, ascending single-dose, Phase I study. Clin Ther 30:1817-30.
7. Lim KS, Cho JY, Kim BH, et al. (2009). Pharmacokinetics and pharmacodynamics of LC15-0444, a novel dipeptidyl peptidas e IV inhibitor, after multiple dosing in healthy volunteers. Br J Clin Pharmacol 68:883-90.
8. Noh YH, Lim HS, Jin SJ, et al. (2012). Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers. Clin Ther 34:1182-94.
9. Rao SS, Kuo B, McCallum RW, et al. (2009). Investigation of colonic and whole-gut transit with wireless motility capsule and radiopaque markers in constipation. Clin Gastroenterol Hepatol 7:53 7-44.
10. Rhee EJ, Lee WY, Yoon KH, et al. (2010). A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes. Diabetes Obes Metab 12:1113-19.
11. Rhee EJ, Lee WY, Min KW, et al.; Gemigliptin Study 006 Group. (2013). Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing me tformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Obes Metab 15:523-30.
12. Su H, Boulton DW, Barros Jr A, et al. (2012). Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human. Drug Metab Dispos 40:1345-56.
13. Vincent SH, Reed JR, Bergman AJ, et al. (2007). Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14Csitagliptin in humans. Drug Metab Dispos 35:533-8.
14. Yang SJ, Min KW, Gupta SK, et al. (2013). A multicentre, multinational, randomized, placebo-controlled , double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes. Diabetes Obes Metab 15:410-16.